Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

233 Press Releases
DateTitleCompany
03 Jul 13 New research data supports safety benefits of Pradaxa in treatment of acute deep vein thrombosis and pulmonary embolism versus warfarin Boehringer Ingelheim
25 Jun 13 Trajenta® (linagliptin): New data on safety and efficacy in Type 2 Diabetes patients with moderate to severe renal impairment Boehringer Ingelheim and Eli Lilly and Company,
Published by
Ogilvy HealthPR London
25 Jun 13 New efficacy and safety data presented for Trajenta® (linagliptin) in Asians with Type 2 Diabetes Boehringer Ingelheim and Eli Lilly and Company,
Published by
Ogilvy HealthPR London
24 Jun 13 Application submitted to the EMA for use of dabigatran etexilate in treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE Boehringer Ingelheim
03 Jun 13 Superiority of afatinib* over comparator chemotherapy for patients with EGFR mutation-positive advanced lung cancer is reinforced by second Phase III study Boehringer Ingelheim,
Published by
Pharmiweb.com
21 May 13 Phase III results: Once-daily tiotropium* effective in symptomatic asthma patients irrespective of their age, allergic status, smoking status and bronchodilator response Boehringer Ingelheim
08 May 13 Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseases Boehringer Ingelheim
24 Apr 13 Boehringer Ingelheim consistently continues growth phase in financial year 2012 Boehringer Ingelheim
26 Mar 13 Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin* Boehringer Ingelheim,
Published by
Business Wire
26 Mar 13 FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate) Boehringer Ingelheim,
Published by
Business Wire
19 Mar 13 Boehringer Ingelheim and Lilly initiate MARLINA™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria Boehringer Ingelheim,
Published by
Business Wire
11 Mar 13 Pharmaco-invasive strategy including Metalyse® delivers comparable clinical outcomes to primary PCI for STEMI patients who could not undergo primary PCI within one hour from first medical contact Boehringer Ingelheim
11 Mar 13 American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education with focus on China in 2013 Boehringer Ingelheim,
Published by
Business Wire
23 Feb 13 Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status Boehringer Ingelheim,
Published by
Business Wire
30 Jan 13 FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD Boehringer Ingelheim
30 Jan 13 FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD Boehringer Ingelheim,
Published by
Business Wire
16 Jan 13 U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC Boehringer Ingelheim,
Published by
Business Wire
08 Jan 13 Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin Boehringer Ingelheim and Eli Lilly and Company,
Published by
Boehringer Ingelheim
10 Dec 12 Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin Boehringer Ingelheim,
Published by
Business Wire
05 Dec 12 New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session Boehringer Ingelheim,
Published by
Business Wire
12 Nov 12 RELY-ABLE® study demonstrates benefits of Pradaxa® (dabigatran etexilate) are maintained for over 4 years Boehringer Ingelheim
10 Nov 12 Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease Boehringer Ingelheim,
Published by
Business Wire
08 Nov 12 RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa® for stroke prevention in AF Boehringer Ingelheim GmbH,
Published by
Business Wire
06 Nov 12 Safety and Efficacy of Pradaxa® (dabigatran etexilate) Reconfirmed in Clinical Setting for VTE Prevention After Total Knee or Hip Replacement Boehringer Ingelheim,
Published by
Business Wire
05 Nov 12 FDA and EMA Reaffirm Important Health Benefits and Safety of Pradaxa® (dabigatran etexilate) for Patients with Atrial Fibrillation Boehringer Ingelheim GmbH,
Published by
Business Wire
15 Oct 12 NICE recommends treatment with alteplase is started as early as possible, within 4.5 hours of onset of ischaemic stroke symptoms Boehringer Ingelheim
02 Oct 12 Analyses presented at EASD support Trajenta® (linagliptin) as effective and well-tolerated for patients with type 2 diabetes with different background therapies Boehringer Ingelheim,
Published by
Business Wire
01 Oct 12 Boehringer Ingelheim’s novel project transfer program enables fast track to launch for biopharmaceuticals Boehringer Ingelheim
12 Sep 12 Asian populations with atrial fibrillation (AF) benefit from better stroke prevention with Pradaxa® (dabigatran etexilate) compared to warfarin Boehringer Ingelheim GmbH,
Published by
Business Wire
03 Sep 12 New data show significant improvements in lung function using combination of tiotropium and olodaterolA in COPD patients Boehringer Ingelheim,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.